Does Australian Clinical Labs pay a dividend?

Australian Clinical Labs offers a trailing dividend yield of about 5.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Australian Clinical Labs financially healthy?

Australian Clinical Labs carries a debt-to-equity ratio of 3.01x and a current ratio of 0.59x, with a market beta of 0.82. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Australian Clinical Labs a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Australian Clinical Labs (ACL) the key facts are: market cap A$435M, P/E 15.7x, revenue A$741M, 52-week range 1.8325-2.97. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Australian Clinical Labs's full fundamentals live

Get Australian Clinical Labs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.